|
Product name
|
Linezolid
|
|
CAS Number
|
165800-03-3
|
|
Synonyms
|
LinezolidandInterMediate;N-{[(5S)-3-[3-fluoro-4-(Morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]Methyl}acetaMide;(S)-N-((3-(3-fluoro-4-Morpholinophenyl)-2-oxooxazolidin-5-yl)Methyl)acetaMide;(S)-N-[[3-(3-Fluoro-4-morpholinophenyl)-2-oxChemicalbooko-5-oxazolidinyl]methyl]acetamide;Linezolid-13C-d3;Acetamide,N-[[(5S)-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-(9CI);Acetamide,N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-,(S)-;PNU100766
|
|
Molecular formula
|
C16H20FN3O4
|
|
Molecular weight
|
337.35
|
|
Purity
|
99%
|
|
Appearance
|
White Powder
|
|
EINECS number
|
605-416-1
|
Linezolid is supplied as a ready-to-use sterile isotonic solution for intravenous infusion. Each mL contains 2 mg of linezolid. Inactive ingredients are sodium citrate, citric acid, and dextrose in an aqueous vehicle for intravenous administration. The sodium (Na+) content is 0.38 mg/mL (5 mEq per 300-mL bag; 3.3 mEq per 200-mL bag; and 1.7 mEq per 100-mL bag).
Linezolid CAS 165800-03-3 Application
For the treatment of infections caused by Gram-positive cocci, the complex infections of skin and soft tissue, uncomplicated infections of skin and soft tissue, treatment ofinfections caused by vancomycin-resistant Enterococcus faecium.